fate therapeutics stock price today

Shares of Fate Therapeutics were trading at 3395 as of February 24. The stock was sold at an average price of 6000 for a total value of 95862000.

Can Fate Therapeutics Stock Rebound After A 20 Drop

Over the last 52-week period shares are down 6436.

. Given that these returns are generally negative long. FATE stock quote history news and other vital information to help you with your stock trading and investing. Get a real-time Fate Therapeutics Inc.

Their forecasts range from 6000 to 14500. Stock was originally listed at a price of 662 in Oct 1 2013. Financial news and information Stock FATE THERAPEUTICS INC.

Stay up to date on the latest stock price chart news analysis fundamentals trading and investment tools. FATEs stock with other industry players reveals that stocks current price change of 666 and that of -6065 over the past 12 months is in competing position with that of Ionis Pharmaceuticals Inc. Volume today is below average.

FATE has a beta of 252 meaning it tends to be more sensitive to market movements. If you had invested in Fate Therapeutics stock at 662 your return over the last 8 years would have been 49804 for an annualized return of 2505 not. View real-time stock prices and stock quotes for a full financial overview.

Dulac III sold 15977 shares of Fate Therapeutics stock in a transaction that occurred on Monday December 20th. What is Fate Therapeutics stock price doing today. Stock news by MarketWatch.

Find the latest Fate Therapeutics Inc. This suggests a possible upside of 2117 from the stocks current price. FATE has a correlation of 020 to the broad based SPY ETF.

FATE Complete Fate Therapeutics Inc. As of February 11 2022 FATE stock price declined to 3780 with 1100893 million shares trading. News Fate Therapeutics IncFATE.

Get Fate Therapeutics Inc FATENASDAQ real-time stock quotes news price and financial information from CNBC. Fate Therapeutics - FATE - Stock Price Today - Zacks Quote Overview. While Guggenheim analyst Michael Schmidt reduced the price target on Fate Therapeutics to 78 from 107 a Buy rating on the shares was assigned to the company.

No significant news for in the past two years. Fate Therapeutics Inc FATE stock is trading at 3528 as of 326 PM on Friday Feb 25 a rise of 133 or 392 from the previous closing price of 3395. Real time Fate Therapeutics FATE stock price quote stock graph news analysis.

The Investor Relations website contains information about Fate Therapeutics Incs business for stockholders potential investors and financial analysts. Moon Michael Rudnicki David Scadden Leonard Zon Alexander Rives. Why Fate Therapeutics Stock Is Sliding Today.

Common Stock FATE Stock Quotes - Nasdaq offers stock quotes market activity data for US and global markets. The stock price of Fate Therapeutics Inc NASDAQ. The sale was disclosed in a legal filing with the Securities Exchange Commission.

The stock has traded between 3285 and 3535 so far today. 13 brokerages have issued 12 month target prices for Fate Therapeutics stock. A high-level overview of Fate Therapeutics Inc.

What is Fate Therapeuticss Beta. NASDAQFATE CFO Edward J. Find real-time FATE - Fate Therapeutics Inc stock quotes company profile news and forecasts from CNN Business.

The Price to Earnings PE ratio a key valuation measure is calculated by dividing the stocks most recent. In comparing Fate Therapeutics Inc. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates.

Fate Therapeutics posted interim results from ongoing studies with its cancer therapy candidates. By Cory Renauer - Aug 20 2021 at 1157AM Key Points. FATE increased by over 1 during intraday trading today.

FATE stock price quote with breaking news financials statistics charts and more. Get the latest Fate Therapeutics FATE detailed stock quotes stock data Real-Time ECN charts stats and more. Investors are responding positively to a bullish research report.

On average they expect Fate Therapeutics stock price to reach 10329 in the next twelve months. The company was founded by Philip Beachy Sheng Ding Rudolf Jaenisch Randall T. Stock analysis for Fate Therapeutics Inc FATENASDAQ GM including stock price stock chart company news key statistics fundamentals and company profile.

Engages in the development of programmed cellular immunotherapies for cancer and immune disorder. IONS which saw its stock price raised by 573 in the last trading and went through a decrease of -3917 in past 12-month.

Fate Fate Therapeutics Inc Stock Overview U S Nasdaq Barron S